Join strategic leaders to tackle the biggest obstacles in CAR T development. Have an opportunity to connect with key decision makers and multiple stakeholders in CAR T Cell Therapies. Starting with discovery and early stage strategies, participants traverse the current landscape including translation, clinical trials, manufacturing, and market access.
Interactive round tables, problem solving and solution-driven live discussions generate actionable strategies that can be implemented to condense the timeline and accelerate curative treatments to the patient around:
Executive Deputy Director, Center for Cellular Immunotherapies
University of Pennsylvania- Penn Medicine
Peter Marks MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)